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TECHNICAL NOTE
Lentiviral gene transfer into human 
and murine hematopoietic stem cells:  
size matters
Kirsten Canté‑Barrett1 , Rui D. Mendes1, Willem K. Smits1, Yvette M. van Helsdingen‑van Wijk1, Rob Pieters2 
and Jules P.  P. Meijerink1*
Abstract 
Contemporary biomedical research increasingly depends on techniques to induce or to inhibit expression of genes in 
hematopoietic stem cells (HSCs) or other primary cells to assess their roles on cellular processes including differentia‑
tion, apoptosis and migration. Surprisingly little information is available to optimize lentiviral transduction of HSCs. We 
have therefore carefully optimized transduction of murine and human HSCs by optimizing vector design, serum‑free 
virus production and virus quantitation. We conclude that the viral RNA length, even in relatively small vectors, is an 
important factor affecting the lentiviral gene transfer on the level of both the virus production and the cellular trans‑
duction efficiency. Efficient transfer of large gene sequences into difficult‑to‑transduce primary cells will benefit from 
reducing the lentiviral construct size.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human immunodeficiency virus-based lentiviral gene 
transfer has been embraced in contemporary laboratory 
practice as an efficient procedure to shuttle gene-encoding 
RNA molecules into target cells, where they are reverse-
transcribed and integrated into the host genome. Third-
generation lentiviral vector systems have proven to be 
safe methods in gene therapy with very low risks of ongo-
ing integrations in the host genome or generation of rep-
lication-competent viral particles [1, 2]. Lentiviruses infect 
both dividing and non-dividing cells, making them ideally 
suited to transduce human and murine hematopoietic stem 
cells (HSCs) [3–6]. Many fields of research often require 
lentiviral constructs that drive gene expression from a pro-
moter as well as a fluorescent reporter expressed from an 
internal ribosomal entry site or secondary promoter. The 
virus production (tested for vectors that encode viral RNA 
ranging from 4 to 7.5  kb in length) [7] and efficiency to 
transduce adherent cell lines seems dependent on the size 
of the lentiviral vector that encodes for the viral RNA. Vec-
tors with viral RNA ranging from 5 to 9 kb generally tested 
decent, whereas those ranging from 10 to 18  kb trans-
duced very poorly [8]. However, the nature of the target cell 
(cell line or primary cells) is crucial and most of the stud-
ies published to date have not addressed the transduction 
efficiency of primary cells. Additionally, it is important to 
control the production process of lentiviral particles (in 
HEK293T cells), and the quantitation method to determine 
the number of competent viral particles produced. Since 
little information is available regarding these variables 
and their effects on lentiviral transduction, we carefully 
optimized lentiviral transfer by optimizing vector design, 
serum-free virus production and quantitation, as well as by 
optimizing transduction of murine and human HSCs.
Methods
Cloning
For fast, highly flexible and reliable cloning purposes, we 
have adapted the third-generation self-inactivating lenti-
viral LeGO-iC2 vector [9] into a Gateway compatible des-
tination vector (LeGO-DEST) by replacing the ApaI/PciI 
2  kb insert with the Gateway ccdB cassette (Life Tech-
nologies). We assembled lentiviral expression constructs 
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in which we cloned a promoter, a gene, a Thosea asigna 
virus 2A (T2A) element [10], and the blue fluorescent 
protein reporter (mTagBFP). These, in combination with 
other lentiviral elements, are flanked by long terminal 
repeats and encode for the viral RNA. Upon translation, 
the gene and BFP moieties are efficiently separated by 
T2A cleavage in target cells (Fig. 1).
Cell line
The human T cell leukemia cell line JURKAT 
(DSMZ, #ACC-282) identity was confirmed by DNA 
fingerprinting and cells were regularly tested for myco-
plasma contamination.
Virus production, concentration and quantification
We optimized HEK293T transfection in DMEM sup-
plemented with 10  % serum using X-tremeGENE HP 
DNA Transfection Reagent (Roche, #06 366 236 001) to 
produce vesicular stomatitis virus-G pseudotyped virus 
particles without the addition of serum (low-serum Opti-
MEM I with Glutamax: Life Technologies, #51985-026), 
in batches of 40  ml (harvest twice, with 24-h intervals, 
ccdB CASSETTESIN-LTR ψ SIN-LTRWPREcPPTRRE
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Fig. 1 Schematic representation of the elements cloned into our Gateway compatible LeGO‑DEST vector. The different elements and their sizes 
(bp) that were cloned into our Gateway compatible LeGO‑DEST vector to generate lentiviral expression vectors of different sizes between SIN‑LTRs: 
4215, 5190 and 5750 bp. SFFV: Spleen Focus Forming Virus promoter, T2A: Thosea asigna virus 2A element, BFP: blue fluorescent protein. Grey boxes 
indicate lentiviral elements in LeGO‑DEST
Page 3 of 6Canté‑Barrett et al. BMC Res Notes  (2016) 9:312 
from two confluent 14-cm dishes starting 2  days after 
transfection, see Additional file  1). Low serum levels 
minimize the risk of premature differentiation of HSCs 
that are subjected to lentiviral transduction. Further-
more, fetal bovine serum can influence transduction 
[11], and we found that increasing amounts of serum 
(ranging from 0 to 10 %) negatively affects transduction 
rates of human HSCs, perhaps due to the aggregation of 
virus particles in the presence of serum proteins (data 
not shown). In relation to the quantitation of intact viral 
particles, the commonly used p24 protein ELISA method 
overestimates the number of functional viruses by the 
detection of incomplete, transduction-deficient viral 
particles as well as soluble p24 protein in the production 
medium [12]. Quantitative RT-PCR of encapsulated viral 
RNA particles is a valuable alternative. We therefore cal-
culate the number of viral particles that we produce by 
quantification of viral RNA copies using RT-qPCR (two 
RNA copies per viral particle, see Additional file 1). RT-
qPCR is performed using primers flanking the cPPT 
region: 5′-AGGTGGAGAGAGAGACAGAGAC-3′ and 
5′-CTCTGCTGTCCCTGTAATAAAC-3′.
Human CD34+ HSC transduction
Human CD34+ HSCs were positively selected from 
umbilical cordblood (Miltenyi Biotec, #130-100-453) and 
stimulated for 16-20 h at a concentration of 1x106 cells/
ml in X-VIVO 10 (Lonza, #BE04-743Q) supplemented 
with 50 ng/ml rhSCF (R&D, #255-SC), 20 ng/ml rhTPO 
(R&D, #288-TP/CF) and 50 ng/ml rhFlt3L (Miltenyi Bio-
tec, #130-093-855). Prior to transduction, add protamine 
sulfate (Sigma, #P4020-1G) to the cells to a final concen-
tration of 4 µg/ml and pipet the concentrated virus (IVSS 
VIVASPIN 20 centrifugation concentration columns, 
Sartorius AG, Sigma-Aldrich, #Z614653-48EA) into a 
50  µg/ml retronectin (r-Fibronectin CH-296: TaKaRa, 
#T100A)-coated 96-well plate (Falcon, #351172). Add 
HSCs on top of the virus to a final volume of 200  µl/
well and mix by gently tapping the plate. Spinoculation: 
centrifuge the cells in the virus-containing medium at 
1800 rpm, 32 °C for 1 h. Incubate the transduced cells at 
37 °C, 5 % CO2 for 24 h before further use.
Results
We set out to relate the length of the viral RNA to the 
efficiency of virus production as well as to the potency of 
these viral batches to transduce the T-cell acute lympho-
blastic leukemia line JURKAT. Our optimized lentiviral 
particle production consistently leads to near equal yields 
for consecutive batches produced from the same lentivi-
ral construct (average variation of 4.3 fold (range 1.3–12 
fold) for repetitive viral batches from 10 different con-
structs). We observed an inverse exponential correlation 
between the length of the viral RNA encoded by the 
construct and the number of viral particles produced by 
HEK293T cells (Fig.  2). RT-qPCR in combination with 
functional titration experiments on a cell line reliably 
determines the number of viral particles required to effi-
ciently transduce target cells. We investigated transduc-
tion efficiencies for virus batches of three different viral 
RNA lengths: 4215, 5190 and 5750 bases. For each con-
struct, three independent viral batches were produced. 
Transduction experiments using serial dilutions of each 
viral batch were performed on JURKAT cells. Four to six 
days after transduction, the percentage of BFP-positive 
(transduced) cells was determined (Fig. 3a, representative 
curves for three independently produced virus batches 
of each construct). While the intensity of BFP signal was 
highest for the virus with the shortest viral RNA and 
lower for longer constructs, in each case the transduced 
population was easily distinguished from non-trans-
duced cells (inset in Fig. 3a). The gene of interest encodes 
a protein with the C-terminal T2A that separates it from 
the BFP (Fig.  3b). The percentage of transduced JUR-
KAT cells remained unchanged for over 3 weeks of cul-
ture (not shown), reflecting stable integration of the viral 
genome in the host DNA. All independently produced 
batches from the same lentiviral construct were virtually 
equally efficient to transduce JURKAT cells, indicating 
that the optimized production, quantitation and trans-
duction procedures are very robust and reproducible. 
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Fig. 2 Relationship between the viral RNA length and production 
of lentiviral particles. The quantity of lentiviral particles that are 
produced (calculated using RT‑qPCR) plotted as a function of the viral 
RNA length (kb). Each point in the plot represents an individual virus 
batch, each time produced using the pLEGO‑DEST backbone and 
the same transfection method and producer cell line (see Additional 
file 1: Supplementary Protocol). The viral RNA length is the length 
of the sequence flanked by the 5′ and 3′ SIN‑LTRs in the lentiviral 
expression vector (see Fig. 1)
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the shortest viral RNA sequence and became progres-
sively lower with increasing length. This is also true for 
all other virus batches produced with viral RNA lengths 
varying from 4 to 9  kb. In general, more viral particles 
with longer viral RNAs seem to be required to achieve 
equal transduction percentages in target cells compared 
to viruses with shorter viral RNAs.
We then tested the efficiency of these viral batches to 
transduce primary human CD34+ HSCs and murine ‘lin-
eage-negative’ bone marrow (Lin− BM) cells. To achieve 
comparable transduction rates for JURKAT, human HSCs 
and mouse Lin− BM, a thousand-fold more virus parti-
cles of the 4215  bp vector are required for the primary 
cells than JURKAT (Fig.  3c). This difference becomes 
even higher (up to 104) for viruses with larger viral RNAs 
(5190 and 5750 bases). Thus, the viral RNA size moder-
ately, albeit significantly, affects the transduction rate of 
a cell line such as JURKAT, but greatly influences trans-
duction efficiencies of freshly isolated human HSCs and 
murine Lin− BM cells. Transduced human HSCs cultured 
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Fig. 3 Transduction efficiency of JURKAT, CD34+ human HSCs and murine Lin− BM with lentiviral vectors of varying sizes. Transduction efficiency 
of different cell types as a function of the amount of virus particles, measured 4–6 days after transduction and expressed as the BFP+ percentage 
of the viable cells. Lentiviruses with three different viral RNA sizes (length between SIN‑LTRs) are compared: 4215 (solid black lines), 5190 (dark-grey 
dashed lines) and 5750 bp (light-grey dashed lines). a Triplicate transductions ± SD of JURKAT cells using serial dilutions of each lentivirus, representa‑
tive of one of three individually produced virus batches. Inset: example flow cytometry plot displaying the BFP+ transduced fraction. b Western blot 
probed with anti‑2A antibody. Total lysates expressing the T2A‑tagged proteins of the 4215 bp (BFP only, no T2A), 5190 and 5750 bp constructs, 
separated from BFP. (asterisk): non‑specific signals. c Triplicate transductions ± SD of human CD34+ HSCs (solid triangles) and murine Lin− BM (solid 
circles) with the three lentiviruses
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on stromal support cells retained an equal percentage of 
BFP-positive cells over the course of 3  weeks, indicat-
ing stable integration (data not shown). To investigate 
whether specific sequences can influence transduction 
efficiency, we generated new vectors harboring double 
or triple BFP sequences (5105 and 5995 bp, respectively; 
Fig.  1). These vectors only differ in size from the single 
BFP construct, but contain the same sequence. Also for 
these viruses, the transduction efficiency in JURKAT 
was highest for the shortest vector and reduced with 
increased length (Fig. 4).
Discussion
We conclude that while larger viral RNA size negatively 
affects both virus production and transduction of target 
cells, other factors can also influence the transduction 
efficiency (e.g. sequence). This is evident from the obser-
vation that the 5750  bp vector (containing the 1535  bp 
gene) revealed lower transduction efficiency than the 
slightly larger triple BFP vector (5995 bp). The transduc-
tion efficiency of human or mouse stem cells decreases 
tremendously for viruses with viral RNAs approaching 
6  kb or larger. Lentiviral vectors encoding smaller viral 
RNA sequences perform better and even a reduction of 
merely 600  bp (5750 versus 5190  bp) already improves 
transduction efficiency by more than threefold (Fig.  3). 
To produce more efficient lentiviruses, reducing the 
viral RNA backbone size by removal of non-essential 
sequences may be effective. Codon optimization alters 
the gene sequence without affecting the protein sequence 
and may also increase transduction efficiency. Addition-
ally, the development of smaller reporter genes or com-
plete removal of the reporter may further enhance the 
transduction efficiency. In the absence of a fluorescent 
reporter, integrated lentiviral constructs into the host 
genome or expression of lentiviral transgene mRNA 
can be quantified by qPCR [13, 14] or RT-qPCR [15], 
respectively. In conclusion, size reduction of lentiviral 
constructs will facilitate efficient transfer of large gene 
sequences into difficult-to-transduce primary cells and 
will be most helpful in many fields of (basic) research.
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Fig. 4 Transduction efficiency of JURKAT with independently generated and different lentiviral vectors of varying sizes. a Transduction efficiency 
of JURKAT cells as a function of the amount of virus particles, measured 4–6 days after transduction and expressed as the BFP+ percentage of the 
viable cells. Lentiviruses with three different viral RNA sizes (length between SIN‑LTRs) are compared: 4215 (1xBFP; black), 5105 (2xBFP; blue) and 
5995 bp (3xBFP; red). Triplicate transductions ± SD using serial dilutions of each lentivirus, representative of one of three individually produced 
virus batches. b Average transduction percentage of the different viruses, measured at the number of virus particles that yielded 75 % in the ‘1xBFP’ 
(4215 bp) vector (indicated by dashed vertical lines in Figs. 3 and 4a)
Page 6 of 6Canté‑Barrett et al. BMC Res Notes  (2016) 9:312 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The use of human umbilical cord materials from healthy individuals was 
approved by the Medical Ethical Review Board of the Erasmus MC Rotterdam 
(MEC‑2009‑430) and in accordance with the Declaration of Helsinki. C57Bl/6 
mice were housed under specific pathogen free conditions at the animal 
facility of Erasmus MC according to institutional guidelines. The use of murine 
bone marrow for the experiments has been approved by the Erasmus MC 
committee for animal welfare (DEC #103‑12‑02) and is in compliance with 
Dutch legislation.
Received: 19 February 2016   Accepted: 3 June 2016
References
 1. Debyser Z. Biosafety of Lentiviral Vectors. Curr Gene Ther. 2003;3:6.
 2. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A 
third‑generation lentivirus vector with a conditional packaging system. J 
Virol. 1998;72:11.
 3. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono 
D. In vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector. Science. 1996;272:5259.
 4. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of 
human CD34+ cells that mediate long‑term engraftment of nod/scid 
mice by hiv vectors. Science. 1999;283:5402.
 5. Naldini L. Lentiviruses as gene transfer agents for delivery to non‑dividing 
cells. Curr Opin Biotechnol. 1998;9:5.
 6. Hong Y, Lee K, Yu SS, Kim S, Kim JG, Shin HY, Kim S. Factors affecting 
retrovirus‑mediated gene transfer to human CD34+ cells. J Gene Med. 
2004;6:7.
 7. al Yacoub N, Romanowska M, Haritonova N, Foerster J. Optimized pro‑
duction and concentration of lentiviral vectors containing large inserts. J 
Gene Med. 2007;9:7.
 8. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the 
packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12:15.
 9. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel 
lentiviral gene ontology (lego) vectors for functional gene analysis. Mol 
Ther. 2008;16:4.
 10. Szymczak AL, Vignali DA. Development of 2a peptide‑based strategies in 
the design of multicistronic vectors. Expert Opin Biol Ther. 2005;5:5.
 11. Denning W, Das S, Guo S, Xu J, Kappes JC, Hel Z. Optimization of the 
transductional efficiency of lentiviral vectors: effect of sera and polyca‑
tions. Mol Biotechnol. 2013;53:3.
 12. Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R. Comparison of 
lentiviral vector titration methods. BMC Biotechnol. 2006;6:34.
 13. Barczak W, Suchorska W, Rubiś B, Kulcenty K. Universal real‑time PCR‑
based assay for lentiviral titration. Mol Biotechnol. 2015;57:2.
 14. Christodoulou I, Patsali P, Stephanou C, Antoniou M, Kleanthous M, 
Lederer CW. Measurement of lentiviral vector titre and copy number by 
cross‑species duplex quantitative pcr. Gene Ther. 2016;23:1.
 15. Lizee G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. 
Real‑time quantitative reverse transcriptase‑polymerase chain reaction 
as a method for determining lentiviral vector titers and measuring 
transgene expression. Hum Gene Ther. 2003;14:6.
